Skip to main content
Top
Published in: BMC Infectious Diseases 1/2011

Open Access 01-12-2011 | Research article

Unnecessary use of fluoroquinolone antibiotics in hospitalized patients

Authors: Nicole L Werner, Michelle T Hecker, Ajay K Sethi, Curtis J Donskey

Published in: BMC Infectious Diseases | Issue 1/2011

Login to get access

Abstract

Background

Fluoroquinolones are among the most commonly prescribed antimicrobials and are an important risk factor for colonization and infection with fluoroquinolone-resistant gram-negative bacilli and for Clostridium difficile infection (CDI). In this study, our aim was to determine current patterns of inappropriate fluoroquinolone prescribing among hospitalized patients, and to test the hypothesis that longer than necessary treatment durations account for a significant proportion of unnecessary fluoroquinolone use.

Methods

We conducted a 6-week prospective, observational study to determine the frequency of, reasons for, and adverse effects associated with unnecessary fluoroquinolone use in a tertiary-care academic medical center. For randomly-selected adult inpatients receiving fluoroquinolones, therapy was determined to be necessary or unnecessary based on published guidelines or standard principles of infectious diseases. Adverse effects were determined based on chart review 6 weeks after completion of therapy.

Results

Of 1,773 days of fluoroquinolone therapy, 690 (39%) were deemed unnecessary. The most common reasons for unnecessary therapy included administration of antimicrobials for non-infectious or non-bacterial syndromes (292 days-of-therapy) and administration of antimicrobials for longer than necessary durations (234 days-of-therapy). The most common syndrome associated with unnecessary therapy was urinary tract infection or asymptomatic bacteriuria (30% of all unnecessary days-of-therapy). Twenty-seven percent (60/227) of regimens were associated with adverse effects possibly attributable to therapy, including gastrointestinal adverse effects (14% of regimens), colonization by resistant pathogens (8% of regimens), and CDI (4% of regimens).

Conclusions

In our institution, 39% of all days of fluoroquinolone therapy were unnecessary. Interventions that focus on improving adherence with current guidelines for duration of antimicrobial therapy and for management of urinary syndromes could significantly reduce overuse of fluoroquinolones.
Appendix
Available only for authorised users
Literature
1.
go back to reference Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS: Fluoroquinolone prescribing in the United States: 1995-2000. Am J Med. 2005, 118: 259-268. 10.1016/j.amjmed.2004.09.015.CrossRefPubMed Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS: Fluoroquinolone prescribing in the United States: 1995-2000. Am J Med. 2005, 118: 259-268. 10.1016/j.amjmed.2004.09.015.CrossRefPubMed
2.
go back to reference Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP: Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinole use. JAMA. 2003, 289: 885-888. 10.1001/jama.289.7.885.CrossRefPubMed Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP: Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinole use. JAMA. 2003, 289: 885-888. 10.1001/jama.289.7.885.CrossRefPubMed
3.
go back to reference Paterson DL: "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004, 38: (Suppl 4):S341-5.CrossRef Paterson DL: "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004, 38: (Suppl 4):S341-5.CrossRef
4.
go back to reference LeBlanc L, Pepin J, Toulouse K, Ouellette MF, Coulombe MA, Corriveau MP, Alary ME: Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis. 2006, 12: 1398-1405.CrossRefPubMedPubMedCentral LeBlanc L, Pepin J, Toulouse K, Ouellette MF, Coulombe MA, Corriveau MP, Alary ME: Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis. 2006, 12: 1398-1405.CrossRefPubMedPubMedCentral
5.
go back to reference Owens RA, Donskey CJ, Gaynes RP, Loo VG, Muto CA: Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008, 46: S19-31. 10.1086/521859.CrossRefPubMed Owens RA, Donskey CJ, Gaynes RP, Loo VG, Muto CA: Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008, 46: S19-31. 10.1086/521859.CrossRefPubMed
6.
go back to reference Aubert G, Carricajo A, Vautrin AC, Guyomarc'h S, Fonsale N, Page D, Brunel P, Rusch P, Zeni F: Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect. 2005, 59: 83-89. 10.1016/j.jhin.2004.07.016.CrossRefPubMed Aubert G, Carricajo A, Vautrin AC, Guyomarc'h S, Fonsale N, Page D, Brunel P, Rusch P, Zeni F: Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J Hosp Infect. 2005, 59: 83-89. 10.1016/j.jhin.2004.07.016.CrossRefPubMed
7.
go back to reference Kallen AJ, Thompson A, Ristaino P, Chapman L, Nicholson A, Sim BT, Lessa F, Sharapov U, Fadden E, Boehler R, Gould C, Limbago B, Blythe D, McDonald LC: Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009, 30: 264-272. 10.1086/595694.CrossRefPubMed Kallen AJ, Thompson A, Ristaino P, Chapman L, Nicholson A, Sim BT, Lessa F, Sharapov U, Fadden E, Boehler R, Gould C, Limbago B, Blythe D, McDonald LC: Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009, 30: 264-272. 10.1086/595694.CrossRefPubMed
8.
go back to reference Lautenbach E, Larosa LA, Kasbekar N, Peng HP, Maniglia RJ, Fishman NO: Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med. 2003, 163: 601-605. 10.1001/archinte.163.5.601.CrossRefPubMed Lautenbach E, Larosa LA, Kasbekar N, Peng HP, Maniglia RJ, Fishman NO: Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med. 2003, 163: 601-605. 10.1001/archinte.163.5.601.CrossRefPubMed
9.
go back to reference Mean M, Pavese P, Vittoz JP, Foroni L, Decouchon C, Stahl JP, Francois P: Prospective assessment of fluoroquinolone use in a teaching hospital. Eur J Clin Microbiol Infect Dis. 2006, 25: 757-763. 10.1007/s10096-006-0221-0.CrossRefPubMed Mean M, Pavese P, Vittoz JP, Foroni L, Decouchon C, Stahl JP, Francois P: Prospective assessment of fluoroquinolone use in a teaching hospital. Eur J Clin Microbiol Infect Dis. 2006, 25: 757-763. 10.1007/s10096-006-0221-0.CrossRefPubMed
10.
go back to reference Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ: Unnecessary use of antimicrobials in hospitalized patients. Arch Intern Med. 2003, 163: 972-978. 10.1001/archinte.163.8.972.CrossRefPubMed Hecker MT, Aron DC, Patel NP, Lehmann MK, Donskey CJ: Unnecessary use of antimicrobials in hospitalized patients. Arch Intern Med. 2003, 163: 972-978. 10.1001/archinte.163.8.972.CrossRefPubMed
11.
go back to reference Belliveau PP, Brennan WP, Rothman AL: Levofloxacin use at an academic teaching institution. Am J Health Syst Pharm. 2000, 57: 1791-1793.PubMed Belliveau PP, Brennan WP, Rothman AL: Levofloxacin use at an academic teaching institution. Am J Health Syst Pharm. 2000, 57: 1791-1793.PubMed
12.
go back to reference Dydek GJ, Souney PF, Matthews SJ: DUE of ciprofloxacin in the treatment of urinary tract infections in hospitalized patients. Hosp Formul. 1992, 27: 185-191.PubMed Dydek GJ, Souney PF, Matthews SJ: DUE of ciprofloxacin in the treatment of urinary tract infections in hospitalized patients. Hosp Formul. 1992, 27: 185-191.PubMed
14.
go back to reference Mandell GL, Bennett JE, Dolin R, eds: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 2010, New York: Churchill Livingstone, 7 Mandell GL, Bennett JE, Dolin R, eds: Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 2010, New York: Churchill Livingstone, 7
15.
go back to reference Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008, 36: 309-32. 10.1016/j.ajic.2008.03.002.CrossRefPubMed Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008, 36: 309-32. 10.1016/j.ajic.2008.03.002.CrossRefPubMed
16.
go back to reference Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM, Killgore G, Tenover FC: Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004, 38: 640-5. 10.1086/381551.CrossRefPubMed Gaynes R, Rimland D, Killum E, Lowery HK, Johnson TM, Killgore G, Tenover FC: Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004, 38: 640-5. 10.1086/381551.CrossRefPubMed
17.
go back to reference Rice LB: The Maxwell Finland Lecture: For the duration-rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis. 2008, 15: 491-6.CrossRef Rice LB: The Maxwell Finland Lecture: For the duration-rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis. 2008, 15: 491-6.CrossRef
18.
go back to reference Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooten TM, Infectious Diseases Society of America, American Society of Nephrology, American Geriatric Society: Infectious Diseases Society of America Guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005, 40: 643-54. 10.1086/427507.CrossRefPubMed Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooten TM, Infectious Diseases Society of America, American Society of Nephrology, American Geriatric Society: Infectious Diseases Society of America Guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005, 40: 643-54. 10.1086/427507.CrossRefPubMed
19.
go back to reference Nicolle LE, Bjornson J, Harding GKM, MacDonell J: Bacteriuria in elderly institutionalized men. N Engl J Med. 1983, 309: 1420-5. 10.1056/NEJM198312083092304.CrossRefPubMed Nicolle LE, Bjornson J, Harding GKM, MacDonell J: Bacteriuria in elderly institutionalized men. N Engl J Med. 1983, 309: 1420-5. 10.1056/NEJM198312083092304.CrossRefPubMed
20.
go back to reference Nicolle LE, Mayhew JW, Bryan L: Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized women. Am J Med. 1987, 83: 27-33.CrossRefPubMed Nicolle LE, Mayhew JW, Bryan L: Prospective randomized comparison of therapy and no therapy for asymptomatic bacteriuria in institutionalized women. Am J Med. 1987, 83: 27-33.CrossRefPubMed
21.
go back to reference Ouslander JG, Schapira M, Schnelle JF, Ulman G, Fingold S, Tuico E, Nigam JG: Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents?. Ann Intern Med. 1995, 122: 749-54.CrossRefPubMed Ouslander JG, Schapira M, Schnelle JF, Ulman G, Fingold S, Tuico E, Nigam JG: Does eradicating bacteriuria affect the severity of chronic urinary incontinence in nursing home residents?. Ann Intern Med. 1995, 122: 749-54.CrossRefPubMed
22.
go back to reference Abutyn E, Mossey J, Berlin JA, Boscia J, Levison M, Pitsakis P, Kaye D: Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women?. Ann Intern Med. 1994, 120: 827-CrossRef Abutyn E, Mossey J, Berlin JA, Boscia J, Levison M, Pitsakis P, Kaye D: Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women?. Ann Intern Med. 1994, 120: 827-CrossRef
Metadata
Title
Unnecessary use of fluoroquinolone antibiotics in hospitalized patients
Authors
Nicole L Werner
Michelle T Hecker
Ajay K Sethi
Curtis J Donskey
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2011
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-11-187

Other articles of this Issue 1/2011

BMC Infectious Diseases 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.